Processa Pharmaceuticals, Inc. (PCSA) - חוב להון עצמי

This price chart illustrates the dynamics of the individual debt-to-equity ratio for Processa Pharmaceuticals (PCSA), which currently stands at 0.00. Processa Pharmaceuticals is integrating environmental principles into the development of antitumor agents to reduce harmful emissions. The business relies on optimizing the composition of established medications to accelerate regulatory approval, while growth is driven by alliances with medical centers rather than the acquisition of third-party assets.

The debt_total_eq_co ratio determines the proportion of total liabilities relative to equity, reflecting the degree of financial leverage and the risk of potential default. By analyzing the level of debt-to-equity, an investor can see the financing structure of Processa Pharmaceuticals (PCSA), which minimizes capital expenditures by outsourcing molecule synthesis and testing to contract research organizations (CRO).